Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals (ALNY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,313,175
  • Shares Outstanding, K 120,814
  • Annual Sales, $ 844,290 K
  • Annual Income, $ -852,820 K
  • 60-Month Beta 0.95
  • Price/Sales 18.18
  • Price/Cash Flow N/A
  • Price/Book 39.02
Trade ALNY with:

Options Overview Details

View History
  • Implied Volatility 64.54% ( -1.58%)
  • Historical Volatility 62.61%
  • IV Percentile 91%
  • IV Rank 73.01%
  • IV High 74.45% on 07/26/21
  • IV Low 37.74% on 10/29/21
  • Put/Call Vol Ratio 1.13
  • Today's Volume 68
  • Volume Avg (30-Day) 1,250
  • Put/Call OI Ratio 0.88
  • Today's Open Interest 52,637
  • Open Int (30-Day) 51,246

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -1.58
  • Number of Estimates 8
  • High Estimate -1.09
  • Low Estimate -2.10
  • Prior Year -1.61
  • Growth Rate Est. (year over year) +1.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
117.58 +7.80%
on 05/12/22
161.11 -21.33%
on 04/26/22
-35.32 (-21.79%)
since 04/25/22
3-Month
117.58 +7.80%
on 05/12/22
180.35 -29.72%
on 04/01/22
-28.25 (-18.23%)
since 02/25/22
52-Week
117.58 +7.80%
on 05/12/22
212.00 -40.21%
on 10/14/21
-12.65 (-9.07%)
since 05/25/21

Most Recent Stories

More News
Alnylam Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new positive results from the six-month primary analysis period of the ILLUMINATE-C Phase 3 open-label...

ALNY : 126.75 (-0.24%)
Alnylam Presents New 18-Month Results from Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational Vutrisiran

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new positive results from an 18-month analysis of exploratory cardiac endpoints in the HELIOS-A Phase...

ALNY : 126.75 (-0.24%)
Alnylam's (ALNY) Marketed Drugs Aid Growth Amid Competition

Alnylam's (ALNY) portfolio of approved drugs is witnessing strong uptake so far while its pipeline is progressing well. However, stiff competition in the target market remains a woe.

ALNY : 126.75 (-0.24%)
NVS : 91.25 (-0.74%)
AGLE : 1.5000 (+9.49%)
APLT : 1.4800 (+0.68%)
Alnylam to Webcast Presentations at Upcoming May Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:

ALNY : 126.75 (-0.24%)
Alnylam (ALNY) Misses on Q1 Earnings, Lowers '22 Revenue View

Alnylam's (ALNY) earnings and sales fall shy of estimates in the first quarter of 2022. The company cuts 2022 guidance for net product revenues. Shares down.

REGN : 690.88 (+0.71%)
ALNY : 126.75 (-0.24%)
NVS : 91.25 (-0.74%)
BMRN : 78.93 (+0.19%)
Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Lags Revenue Estimates

Alnylam (ALNY) delivered earnings and revenue surprises of -3.63% and 12.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ALNY : 126.75 (-0.24%)
HOOK : 1.5300 (+4.08%)
Alnylam Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2022 and reviewed recent business...

ALNY : 126.75 (-0.24%)
7 Potential Biotech Stocks Buyout Targets in 2022

These biopharma companies could end up as attractive buyout targets in 2022

ALNY : 126.75 (-0.24%)
NVS : 91.25 (-0.74%)
RHHBY : 42.9900 (-0.54%)
AMGN : 253.01 (+0.44%)
M&As in Spotlight With GSK Announcement: 3 Biotechs in Focus

We discuss a few companies like uniQure (QURE), CRISPR Therapeutics (CRSP) and Alnylam Pharmaceuticals (ALNY) with solid product portfolios and deep pipelines, which make them attractive candidates for...

GSK : 44.97 (-0.07%)
ALNY : 126.75 (-0.24%)
HALO : 46.29 (+3.28%)
QURE : 14.12 (-0.56%)
CRSP : 54.55 (+4.14%)
Alnylam to Webcast Conference Call Discussing First Quarter 2022 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2022 on Thursday, April...

ALNY : 126.75 (-0.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The company's pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas - genetic medicines, cardio-metabolic...

See More

Key Turning Points

3rd Resistance Point 131.11
2nd Resistance Point 129.47
1st Resistance Point 128.11
Last Price 126.75
1st Support Level 125.11
2nd Support Level 123.47
3rd Support Level 122.11

See More

52-Week High 212.00
Fibonacci 61.8% 175.93
Fibonacci 50% 164.79
Fibonacci 38.2% 153.65
Last Price 126.75
52-Week Low 117.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar